Table 1.
Summary of studies
| First author | Year | Patients (No.) | Ulcer area (cm2) | History of ulcer | Intervention measure | Comparison intervention | Follow-up time | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| TG | CG | |||||||
| Gentzkow | 1996 | 37 | 13 | >1 | ≥6 months | Dermagraft | CT | 14 months |
| Richard | 1997 | 109 | 126 | >1 | 45 weeks | Dermagraft | CT | 32 weeks |
| Veves | 2001 | 112 | 96 | 1-16 | ≥2 weeks | Graftskin | CT | 3 months |
| Jason | 2002 | 24 | 22 | 1-20 | ≥2 weeks | Dermagraft | CT | NR |
| Sams | 2002 | 9 | 8 | 1-16 | ≥2 weeks | Graftskin | CT | 3 months |
| Caravaggi | 2003 | 43 | 36 | >2 | ≥1 months | Hyalograft | CT | 11 weeks |
| Marston | 2003 | 130 | 115 | 1-20 | ≥2 weeks | Dermagraft | CT | 4 weeks |
| Luigi | 2011 | 90 | 90 | >1 | ≥2 weeks | Hyalograft | CT | 20 weeks |
TG: Treatment group; CG: Control group; CT: Conventional treatment; NR: Not reported; Dermagraft: Human fibroblast-derived dermis; Graftskin: Living human skin equivalents; Hyalograft: HYAFF 11-based autologous dermal and epidermal grafts.